Viewing Study NCT06657157


Ignite Creation Date: 2025-12-24 @ 6:35 PM
Ignite Modification Date: 2025-12-25 @ 4:05 PM
Study NCT ID: NCT06657157
Status: RECRUITING
Last Update Posted: 2025-12-18
First Post: 2024-10-19
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma
Sponsor: Comprehensive Cancer Center Munich (CCCM)
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Outcomes Module Eligibility Module Contacts Locations Module